270 related articles for article (PubMed ID: 36207571)
1. Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.
Coleman MP
Neurotherapeutics; 2022 Jul; 19(4):1133-1144. PubMed ID: 36207571
[TBL] [Abstract][Full Text] [Related]
2. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss.
White MA; Lin Z; Kim E; Henstridge CM; Pena Altamira E; Hunt CK; Burchill E; Callaghan I; Loreto A; Brown-Wright H; Mead R; Simmons C; Cash D; Coleman MP; Sreedharan J
Acta Neuropathol Commun; 2019 Oct; 7(1):166. PubMed ID: 31661035
[TBL] [Abstract][Full Text] [Related]
3. Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1G93A mouse model of amyotrophic lateral sclerosis.
Peters OM; Lewis EA; Osterloh JM; Weiss A; Salameh JS; Metterville J; Brown RH; Freeman MR
Hum Mol Genet; 2018 Nov; 27(21):3761-3771. PubMed ID: 30010873
[TBL] [Abstract][Full Text] [Related]
4. Sarm1 knockout modifies biomarkers of neurodegeneration and spinal cord circuitry but not disease progression in the mSOD1
Collins JM; Atkinson RAK; Matthews LM; Murray IC; Perry SE; King AE
Neurobiol Dis; 2022 Oct; 172():105821. PubMed ID: 35863521
[TBL] [Abstract][Full Text] [Related]
5. SARM1 is a metabolic sensor activated by an increased NMN/NAD
Figley MD; Gu W; Nanson JD; Shi Y; Sasaki Y; Cunnea K; Malde AK; Jia X; Luo Z; Saikot FK; Mosaiab T; Masic V; Holt S; Hartley-Tassell L; McGuinness HY; Manik MK; Bosanac T; Landsberg MJ; Kerry PS; Mobli M; Hughes RO; Milbrandt J; Kobe B; DiAntonio A; Ve T
Neuron; 2021 Apr; 109(7):1118-1136.e11. PubMed ID: 33657413
[TBL] [Abstract][Full Text] [Related]
6. The chemical biology of NAD
Icso JD; Thompson PR
Curr Opin Chem Biol; 2022 Aug; 69():102176. PubMed ID: 35780654
[TBL] [Abstract][Full Text] [Related]
7. SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
Gerdts J; Brace EJ; Sasaki Y; DiAntonio A; Milbrandt J
Science; 2015 Apr; 348(6233):453-7. PubMed ID: 25908823
[TBL] [Abstract][Full Text] [Related]
8. Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients.
Bloom AJ; Mao X; Strickland A; Sasaki Y; Milbrandt J; DiAntonio A
Mol Neurodegener; 2022 Jan; 17(1):1. PubMed ID: 34991663
[TBL] [Abstract][Full Text] [Related]
9. SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.
Summers DW; Gibson DA; DiAntonio A; Milbrandt J
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6271-E6280. PubMed ID: 27671644
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxin-mediated potent activation of the axon degeneration regulator SARM1.
Loreto A; Angeletti C; Gu W; Osborne A; Nieuwenhuis B; Gilley J; Merlini E; Arthur-Farraj P; Amici A; Luo Z; Hartley-Tassell L; Ve T; Desrochers LM; Wang Q; Kobe B; Orsomando G; Coleman MP
Elife; 2021 Dec; 10():. PubMed ID: 34870595
[TBL] [Abstract][Full Text] [Related]
11. Looking for answers far away from the soma-the (un)known axonal functions of TDP-43, and their contribution to early NMJ disruption in ALS.
Ionescu A; Altman T; Perlson E
Mol Neurodegener; 2023 May; 18(1):35. PubMed ID: 37259156
[TBL] [Abstract][Full Text] [Related]
12. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.
Geisler S; Doan RA; Cheng GC; Cetinkaya-Fisgin A; Huang SX; Höke A; Milbrandt J; DiAntonio A
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484833
[TBL] [Abstract][Full Text] [Related]
13. Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease.
Peters OM; Weiss A; Metterville J; Song L; Logan R; Smith GA; Schwarzschild MA; Mueller C; Brown RH; Freeman M
Neurobiol Dis; 2021 Jul; 155():105368. PubMed ID: 33892050
[TBL] [Abstract][Full Text] [Related]
14. SARM1 acts downstream of neuroinflammatory and necroptotic signaling to induce axon degeneration.
Ko KW; Milbrandt J; DiAntonio A
J Cell Biol; 2020 Aug; 219(8):. PubMed ID: 32609299
[TBL] [Abstract][Full Text] [Related]
15. The SARM1 axon degeneration pathway: control of the NAD
Figley MD; DiAntonio A
Curr Opin Neurobiol; 2020 Aug; 63():59-66. PubMed ID: 32311648
[TBL] [Abstract][Full Text] [Related]
16. The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products.
Garb J; Amitai G; Lu A; Ofir G; Brandis A; Mehlman T; Kranzusch PJ; Sorek R
PLoS One; 2024; 19(4):e0302251. PubMed ID: 38635746
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration.
Loreto A; Hill CS; Hewitt VL; Orsomando G; Angeletti C; Gilley J; Lucci C; Sanchez-Martinez A; Whitworth AJ; Conforti L; Dajas-Bailador F; Coleman MP
Neurobiol Dis; 2020 Feb; 134():104678. PubMed ID: 31740269
[TBL] [Abstract][Full Text] [Related]
18. cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons.
Sasaki Y; Engber TM; Hughes RO; Figley MD; Wu T; Bosanac T; Devraj R; Milbrandt J; Krauss R; DiAntonio A
Exp Neurol; 2020 Jul; 329():113252. PubMed ID: 32087251
[TBL] [Abstract][Full Text] [Related]
19. Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Clark JA; Southam KA; Blizzard CA; King AE; Dickson TC
J Chem Neuroanat; 2016 Oct; 76(Pt A):35-47. PubMed ID: 27038603
[TBL] [Abstract][Full Text] [Related]
20. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD
Sasaki Y; Nakagawa T; Mao X; DiAntonio A; Milbrandt J
Elife; 2016 Oct; 5():. PubMed ID: 27735788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
